Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
Authors
Keywords
-
Journal
Cancers
Volume 12, Issue 7, Pages 1867
Publisher
MDPI AG
Online
2020-07-14
DOI
10.3390/cancers12071867
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B
- (2020) George V. Papatheodoridis et al. JOURNAL OF HEPATOLOGY
- Neutrophil‐to‐lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
- (2020) Toshifumi Tada et al. LIVER INTERNATIONAL
- Indication of suitable transarterial chemoembolization and multikinase inhibitors for intermediate stage hepatocellular carcinoma
- (2020) Shigeo Shimose et al. Oncology Letters
- Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma
- (2020) Sakura Kirino et al. PLoS One
- Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study
- (2020) Shigeo Shimose et al. Nutrients
- Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
- (2020) Hideki Iwamoto et al. Cancers
- Tumor Hypervascularity and hand-foot-skin reaction predict better outcomes in combination treatment of TACE and Sorafenib for intermediate hepatocellular carcinoma
- (2019) Enxin Wang et al. BMC CANCER
- Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision‐tree analysis after propensity score matching
- (2019) Shigeo Shimose et al. HEPATOLOGY RESEARCH
- Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan
- (2019) Sadahisa Ogasawara et al. INVESTIGATIONAL NEW DRUGS
- Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
- (2019) Kazuomi Ueshima et al. Cancers
- Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study
- (2019) Masatoshi Kudo et al. Cancers
- REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
- (2019) Tatsuya Yamashita et al. JOURNAL OF GASTROENTEROLOGY
- Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
- (2019) Tim A. Labeur et al. LIVER INTERNATIONAL
- Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study
- (2018) Sheng-Long Ye et al. BMC CANCER
- Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
- (2018) Richard S. Finn et al. JOURNAL OF HEPATOLOGY
- EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
- (2018) Peter R. Galle et al. JOURNAL OF HEPATOLOGY
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Hepatocellular carcinoma
- (2018) Alejandro Forner et al. LANCET
- Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma
- (2018) Masatoshi Kudo Liver Cancer
- Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology Summary
- (2018) Supriya G. Mohile et al. Journal of Oncology Practice
- Molecular therapies and precision medicine for hepatocellular carcinoma
- (2018) Josep M. Llovet et al. Nature Reviews Clinical Oncology
- A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD
- (2018) Takumi Kawaguchi et al. Scientific Reports
- Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions: Multicenter analysis
- (2018) Atsushi Hiraoka et al. Cancer Medicine
- Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
- (2018) Tim A. Labeur et al. Liver Cancer
- Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses
- (2017) Toshiyuki Tamai et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis
- (2017) Ping Wang et al. Expert Review of Gastroenterology & Hepatology
- Appetite Loss as an Adverse Effect During Treatment with EGFR-TKIs in Elderly Patients with Non-small Cell Lung Cancer
- (2016) MINEHIKO INOMATA et al. ANTICANCER RESEARCH
- Hepatocellular carcinoma: From diagnosis to treatment
- (2016) Miral Sadaria Grandhi et al. SURGICAL ONCOLOGY-OXFORD
- Discontinuation of anti-VEGF cancer therapy promotes metastasis through a liver revascularization mechanism
- (2016) Yunlong Yang et al. Nature Communications
- New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions
- (2015) Makoto Chuma et al. HEPATOLOGY RESEARCH
- Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
- (2015) Philip J. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of percutaneous radiofrequency ablation and CyberKnife®for initial solitary hepatocellular carcinoma: A pilot study
- (2015) Kazue Shiozawa WORLD JOURNAL OF GASTROENTEROLOGY
- Disparities by Race, Age, and Sex in the Improvement of Survival for Major Cancers
- (2015) Chenjie Zeng et al. JAMA Oncology
- Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib
- (2014) Maria Reig et al. JOURNAL OF HEPATOLOGY
- Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries
- (2014) Camillo Porta et al. Cancer Medicine
- 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults
- (2013) Paul A. James et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Cancer Cachexia in the Age of Obesity: Skeletal Muscle Depletion Is a Powerful Prognostic Factor, Independent of Body Mass Index
- (2013) Lisa Martin et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma
- (2013) Ju-Yeon Cho et al. LIVER INTERNATIONAL
- Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib
- (2012) Taiga Otsuka et al. HEPATOLOGY RESEARCH
- Angiotensin II type 1 receptor antagonist prevents hepatic carcinoma in rats with nonalcoholic steatohepatitis
- (2012) Yosui Tamaki et al. JOURNAL OF GASTROENTEROLOGY
- Biological, Clinical, and Psychosocial Correlates at the Interface of Cancer and Aging Research
- (2012) W. Dale et al. JNCI-Journal of the National Cancer Institute
- Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib
- (2011) Manabu Morimoto et al. HEPATOLOGY RESEARCH
- Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
- (2010) Riccardo Lencioni et al. SEMINARS IN LIVER DISEASE
- Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab
- (2008) M. Scartozzi et al. ANNALS OF ONCOLOGY
- Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study
- (2008) Jean-Philippe Spano et al. LANCET
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started